In routine clinical practice, breast tumors are treated differently depending on the expression levels of estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor HER2/ERBB213, and each subtype is associated with different treatment responses and clinical outcomes. This evidence concerns the gene ERBB2 and breast neoplasm.